IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issues
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)